Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

Podobne zapisy

• Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study
  od: Yoon, Hee-Young, i wsp.
  Wydane: (2020)
• Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
  od: Yang, Hua, i wsp.
  Wydane: (2016)
• The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
  od: Wu, Shang-Gin, i wsp.
  Wydane: (2020)
• Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
  od: Chang, Yoon Soo, i wsp.
  Wydane: (2016)
• Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor–tyrosine kinase inhibitors
  od: Huang-Chih Chang, i wsp.
  Wydane: (2017-03-01)